Stockreport

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting [Yahoo! Finance]

Cardiff Oncology, Inc.  (CRDF) 
PDF regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment options SAN DIEGO, Calif., April 17, 2026 (GLOB [Read more]